Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Net Cash Flow of $6.9 million for Q3 2025, up 262.77% year-over-year from $1.9 million in Q3 2024, and up 506.56% quarter-over-quarter from $1.1 million in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Net Cash Flow history runs 13 years deep, the most recent figure standing at $6.9 million for Q3 2025.
- In Q3 2025, Net Cash Flow rose 262.77% year-over-year to $6.9 million; the TTM figure through Dec 2025 stood at $9.8 million (up 181.66% YoY), while the FY2024 annual figure was $3.5 million, up 205.95% from the prior year.
- Net Cash Flow for Q3 2025 stood at $6.9 million, up from $1.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $32.0 million in Q1 2022, with the low at -$31.3 million in Q2 2022.
- The 5-year median for Net Cash Flow is $1.0 million (2023), against an average of -$3.1 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow sank 1383.47% in 2022, then soared 835.59% in 2024.
- Corbus Pharmaceuticals Holdings' Net Cash Flow stood at -$12.1 million in 2021, then jumped by 137.64% to $4.6 million in 2022, then plunged by 45.71% to $2.5 million in 2023, then plunged by 189.9% to -$2.2 million in 2024, then surged by 411.87% to $6.9 million in 2025.
- Business Quant data shows CRBP's Net Cash Flow at $6.9 million in Q3 2025, $1.1 million in Q2 2025, and $1.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 6.94 Mn |
| Sep 30, 2025 | 6.94 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -2.23 Mn |
| Dec 31, 2024 | -2.23 Mn |
| Sep 30, 2024 | -4.26 Mn |
| Sep 30, 2024 | -4.26 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Mar 31, 2024 | 379,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | 2.48 Mn |
| Dec 31, 2023 | 2.48 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Jun 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.02 Mn |